Latest Articlesddd

Data From ASCO and Data from the Internet

June 6, 2017 0

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology …

FDA Breakthrough Therapy Designation for Alnylam’s RNAi Drug Givosiran

June 2, 2017 0

Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the …

CAR-T Great News and About the Biotech Sector in General

June 1, 2017 0

It is obvious that the CAR-T approach to cancer treatment is here to stay and to …

Array and Bristol-Myers Collaborate to Defeat Colorectal Cancer

May 30, 2017 0

Array Biopharma (ARRY) and Bristol-Myers Squibb (BMY) announced a clinical research collaboration to investigate the safety, …

Prohost Letter #409

May 25, 2017 0

Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. …

GlycoMimetics: A Lot to Tell at the ASCO Meeting

May 25, 2017 0

GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most …

Why Amgen’s Bone Builder Drug Evenity Will Be Delayed Approval in Spite of Superior Efficacy Results

May 23, 2017 0

Amgen’s (AMGN) and UCB's drug Evenity (romosozumab), which, in long and large 24 months of clinical …

Why Incyte’s Product Epacadostat’s Positive Results Are So Important

May 22, 2017 0

As a matter of fact, we consider Incyte’s (INCY) drug epacadostat’s good results extremely important. The reason? Two …

Calming Down PTC Therapeutics Investors’ Concerns. More Good News from Sangamo. AERIE’s Glaucoma Drug NDA

May 18, 2017 0

PTC THERAPEUTICS Why Buying Emflaza? Buying Emflaza, a steroid approved by the FDA for Duchenne muscular …

Why Akebia Therapeutics’ Stock is Outperforming

May 16, 2017 0

AKEBIA THERAPEUTICS? Akebia Therapeutics (AKBA) whose stock trades on the NASDAQ is outperforming. The firm’s drug …

The Value of Sangamo, Merck and AstraZeneca News

May 15, 2017 0

GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that …

Who Is the New FDA Commissioner? What Happened to Roche’s Immunotherapy Drug?

May 11, 2017 0

AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of …

Array Biopharma: When Clinical Trial Results Talk

May 10, 2017 0

Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating …

KITE Pharma: The Risk Versus the Reward

May 9, 2017 0

Indeed, Saving One Life is Important. Yet, Important Too is Saving Many Lives The Risk Vs. …

Why Epizyme’s Upcoming Presentation Is More Than Exciting

May 8, 2017 0

EPIZYME Many oncologists, we believe, must be impatient to learn about the outcome of a first-in-class …

Novartis Agreements with Celyad and Bluebird Bio Say a Lot

May 5, 2017 0

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). …

What Makes Merck and Array Shareholders Edgy

May 3, 2017 0

MERCK Merck (MRK) has beaten analysts’ expectations generating $9.4 billion for revenues in the first quarter …

Amgen: A Revolutionary Migraine Product Might Become the First to Reach the Clinic

May 1, 2017 0

MIGRAINE Migraine might have a new potent preventive treatment on the market in the near future. …

ImmunoGen: What About Now?

April 28, 2017 0

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the …

Prohost Letter #408

April 25, 2017 0

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the …